Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by Biobobon Oct 28, 2022 12:15pm
195 Views
Post# 35056100

Chronic undervaluation

Chronic undervaluationThe total lack of interest from buyers at 2 times sales is disturbing.. considering there is potential (FDA Fast Track potential, Nash p.3 potential).. considering Marathon is willing to lend them money for 100M max... stupid volumes, no analyst report to support the stock even if they want to raise money in a near future.  Many other tax loss candidates than Th this year also.  I don't get it that selling this story can be so dam difficult.  Paul was hailed as a great salesman by our Chairwomen.... it's making all shareholders angry atm that nothing can be done about it because these markets are sooooooooooo difficult. Yes but 2 times sales once again and some giganourmous potential not that far away is clearly not told and pushed and hussled to potential investors the way it should.  It can't considering the stupid.. I repeat stupid value and recognition we shareholders are getting atm.  But for that someone has to pound the table overthere.
<< Previous
Bullboard Posts
Next >>